Manchester researchers are combining enzyme engineering and AI to develop new biocatalytic manufacturing routes to important medicines. Supported by the Gates Foundation, the team has targeted lenacapavir, a long-acting HIV prevention drug. Using directed evolution, researchers evaluated more than 12,000 enzyme variants, producing an enzyme that achieved more than 98% substrate conversion, 90% isolated yield and 99.5% enantiomeric purity.
AI-designed enzymes to produce therapeutics for global health
calendar_today
November 11, 2026
domain
university-of-manchester